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Abstract
Background: The ectodomain of matrix protein 2 (M2e) of influenza A virus is a rationale target antigen candidate for the
development of a universal vaccine against influenza as M2e undergoes little sequence variation amongst human influenza
A strains. Vaccine-induced M2e-specific antibodies (Abs) have been shown to display significant cross-protective activity in
animal models. M2e-based vaccine constructs have been shown to be more protective when administered by the intranasal
(i.n.) route than after parenteral injection. However, i.n. administration of vaccines poses rare but serious safety issues
associated with retrograde passage of inhaled antigens and adjuvants through the olfactory epithelium. In this study, we
examined whether the sublingual (s.l.) route could serve as a safe and effective alternative mucosal delivery route for
administering a prototype M2e-based vaccine. The mechanism whereby s.l. immunization with M2e vaccine candidate
induces broad protection against infection with different influenza virus subtypes was explored.
Methods and Results: A recombinant M2 protein with three tandem copies of the M2e (3M2eC) was expressed in
Escherichia coli. Parenteral immunizations of mice with 3M2eC induced high levels of M2e-specific serum Abs but failed to
provide complete protection against lethal challenge with influenza virus. In contrast, s.l. immunization with 3M2eC was
superior for inducing protection in mice. In the latter animals, protection was associated with specific Ab responses in the
lungs.
Conclusions: The results demonstrate that s.l. immunization with 3M2eC vaccine induced airway mucosal immune
responses along with broad cross-protective immunity to influenza. These findings may contribute to the understanding of
the M2-based vaccine approach to control epidemic and pandemic influenza infections.
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Introduction
Current seasonal influenza virus vaccines are composed of
antigenic determinants from three virus strains, two influenza A
virus subtypes (H1N1 and H3N2) and one influenza B virus strain,
that are predicted to cause disease during the upcoming influenza
season. The feature of the vaccines is to induce neutralizing
antibodies (Abs) against the two major viral glycoproteins, the
hemagglutinin (HA) and neuraminidase (NA) that undergo
frequent antigenic variations [1]. Since the efficacy of these
vaccines is by and large strain-specific and hence relatively weak
against antigenic variants [2], it is necessary to revaccinate with
the updated strains every year. This has led to efforts to develop a
universal vaccine capable of inducing protection against different
influenza virus subtypes [3].
M2 is a transmembrane protein containing 97 amino acids and
the native protein is a homotetramer linked by two disulfide linked
dimers [4]. The tetrameric M2 protein forms a proton channel
and plays an important role in uncoating the virus during viral
entry [5,6]. M2 protein is abundant on the surfaces of influenza A
virus-infected cells but rare in mature virions [7,8]. Ito et al. have
demonstrated that the ectodomain of M2 protein (M2e), which
contains 24 amino acids, is highly conserved among influenza A
viruses [9]. Because of these properties, M2e has been considered
as an attractive target for inducing cross-protection against
different influenza A viruses subtypes [3]. It has been shown that
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and reduce plaque size in vitro [8]. Passive immunization with these
Abs reduced viral replication in the lungs of mice infected with
influenza A virus [10]. Abs specific for M2e were rarely induced in
human during natural influenza virus infection [11,12] and in
mice after experimental infection [13]. To overcome the low
immunogenicity of M2 [14,15,16], a number of approaches have
been attempted including fusion of M2 protein with carrier
molecules like gluthation S-transferase,hepatitis B virus core
(HBc), keyhole limpet hemocyanin (KLH), or Neisseria meningitides
outer membrane protein complex (OMPC), or by co-administra-
tion with adjuvants such as flagellin and cholera toxin (CT)
[17,18,19,20,21,22,23,24,25,26].
The route of vaccine administration is critical for successful
immunization [27]. Mucosal immune responses are important for
the first line of defense because most microbial pathogens invade
via mucosal surfaces [28]. It has been demonstrated that intranasal
(i.n.) administration of M2 vaccines could induce better protection
against influenza virus than parenteral immunization [18,29].
However, i.n. administration of vaccines and certain adjuvants has
met with safety issues associated with retrograde transport of
immunogens or adjuvants to the central nervous system [30,31].
Recently we have demonstrated that sublingual (s.l.) mucosa is
an efficient site for the induction of broad-spectrum of immune
responses [32]. S.l. administration of live or inactivated influenza
virus induced Ab and T cell responses in the local mucosa of the
respiratory tract and in the systemic compartment and protection
of mice from lethal infection [33]. Importantly, unlike the i.n.
route, s.l. immunization does not redirect vaccines to the CNS
[32,33].
In this study we examined the suitability of the s.l. immunization
with M2-based vaccine for induction of broad protection against
infection with different influenza virus subtypes in comparison
with i.n., intradermal (i.d.) and intramuscular (i.m.) immuniza-
tions.
Results
Expression of soluble recombinant M2 proteins
Since the deletion of amino acids 26–55 of M2 protein from A/
Aichi/2/68 (H3N2) can improve solubility of the protein
expressed from E. coli [17], gene without residues 26–55 of M2
protein from A/PR/8 (H1N1) was chemically synthesized and
inserted into pET15b vector to express the target proteins as a
fusion of his-tag at the N terminus (Fig. 1A). We prepared two
constructs expressing one (M2eC) or three tandem copies (3M2eC)
of M2e conjugated to C-terminus sequence of M2 protein. Each
protein expressed from E. coli BL21 (DE3) strain was soluble and
purified by His-Tag affinity chromatography. The endotoxin level
of each protein was less than 5 EU/mg (data not shown). The
purified proteins were confirmed by western blot using M2e-
specific monoclonal Ab, 14C2 [8] (Fig. 1B). The result showed that
M2eC and 3M2eC were 10.5 and 16.7 kDa, respectively.
Immunogenicity of 3M2eC
We first tested the immunogenicity of 3M2eC formulated with
and without CT adjuvant when given intranasally. The immuno-
genicity of 3M2eC was compared to that of the single M2e
protein. Each group of BALB/c mice was immunized i.n. twice
with M2eC, 3M2eC alone, or 3M2eC mixed with CT (3M2eC/
CT). As shown in Fig. 2A, mice immunized with 3M2eC in
combination with CT showed significantly higher IgG titer than
that seen in animals immunized with 3M2eC only. Mice
immunized with M2eC developed significantly lower serum IgG
response when compared to that induced in other two groups.
Similarly, significant IgA titers were detected in saliva of mice
immunized with CT adjuvanted 3M2eC as compared to that
induced in saliva of other two groups (Fig. 2B). 3M2eC was more
immunogenic than the M2eC construct and in consequence
3M2eC protein construct was used as a vaccine candidate for
further experiments in this study.
S.l. immunization with 3M2eC induced systemic immune
responses
It has been shown that i.n. administration of M2-based vaccine
is more effective than systemic routes for protection against
influenza virus infection [26,34]. However, i.n. immunization
remains a safety concern because of potential retrograde transport
of vaccine components to the CNS [30,31]. In the earlier studies
we demonstrated that s.l. administration with ovalbumin or
inactivated virus induced cellular and humoral immunity compa-
rable to i.n. immunization without redirection of antigens to the
CNS [32,33]. We further examined s.l. immunization with
Figure 1. Construction of plasmids and purification of M2 proteins. (A) The synthetic M2eC or 3M2eC genes without hydrophobic region
(amino acids 26–55) from PR8 virus were cloned into pET15b vector (B). The recombinant proteins expressed in E. coli were purified by His-tag affinity
chromatography and detected by Western blot using M2e-specific monoclonal Ab, 14C2.
doi:10.1371/journal.pone.0027953.g001
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with immunizations via i.n. and systemic routes (i.m. and i.d.). As
shown in Fig. 2C, s.l. immunization with 3M2eC induced
substantial M2e-specific serum IgG Ab response, although the
level of Abs is lower than that induced by i.m., i.d., or i.n.
immunization. Of note, i.n. immunization induced high level of
specific IgG in plasma comparable to that induced by systemic
immunizations. In addition, immunization with 3M2eC induced
predominantly IgG1 as compared to IgG2a subclass (Fig. 2C).
To determine M2e-specific Ab response, full length tetrameric
M2-expressing Hela cells [13] were used and Abs recognizing M2e
on the surface of the cells were measured by ELISA. As shown in
Fig. 2D, all the immunized mice exhibited high levels of M2e-
specific Ab response. The level of M2e-specific Abs determined by
ELISA with coated M2e was consistent with that determined by
ELISA using 3M2eC protein.
Protection against challenge with virus containing
homologous M2e sequence
We next evaluated the protective efficacy of the 3M2eC vaccine
candidate against infection with influenza virus containing the
same M2e sequence upon different immunization routes. BALB/c
mice were immunized with 3M2eC twice at 2 week interval. Three
weeks after the last immunization the mice were challenged i.n.
with 10 LD50 of mouse-adapted A/PR/8 virus. As shown in
Fig. 3A, only 50% of mice immunized via i.m. or i.d. route
survived the challenge with lethal dose of PR8 virus challenge,
while 100% of mice immunized sublingually or intranasally
survived the challenge (Fig. 3A). As expected, none of the mice in
the control unimmunized group survived the lethal infection.
Significant body weight loss was observed in the groups of mice
vaccinated via systemic routes (losing 33% and 28% of the initial
body weight in groups of mice immunized via the i.m. and i.d.
routes, respectively), while s.l. immunized mice lost less than 10%
of initial body weight after the challenge (Fig. 3B). This result
showed that s.l. administration with two doses of the 3M2eC
protein provided complete protection against lethal influenza virus
infection.
Protection against challenge with virus containing
heterologous M2e sequence
Although it is known that M2e is highly conserved among
influenza A viruses [9,35], we compared 10,551 M2e sequences of
influenza A virus strains available from the U.S. National Center
for Biotechnology Information (NCBI) with that of PR8 virus to
examine homology of M2e sequence among the influenza A
viruses (Table 1). We found that the most variable viruses contain
6 mismatched amino acids within 23 amino acids of M2e. To
evaluate the efficacy of the 3M2eC vaccine candidate in induction
of cross-protection, we selected a mouse adapted highly patho-
genic A/Aquatic Bird/Korea/W81/05 (H5N2) virus that contains
6 mismatched amino acids against the M2e sequence of the PR8
virus (Table 2) [36] for challenge. While the systemic immuniza-
tion routes failed to protect the mice against the lethal infection
with H5N2 virus, the i.n. and s.l. immunization groups conferred
100% and 67% protection, respectively (Fig. 3C). Morbidity was
Figure 2. Immunogenicity of 3M2eC (A & B): BALB/c mice were immunized i.n. with 10 ug of M2eC, 3M2eC, or 3M2eC plus 2 ug of
CT on day 0 and 14. Mice received PBS serve as control group. Sera and saliva were collected on day 14 after last immunization. Levels of M2e-
specific IgG in sera (A) and IgA in saliva (B) were determined by ELISA. Ab levels induced by different immunization methods (C & D): BALB/c mice
were administered on day 0 and 14 with 10 ug of 3M2eC protein plus 2 ug of CT for i.n. and s.l. immunizations or plus alum i.d. or i.m. immunizations.
Sera were collected on day 14 after the last immunization. Ab and analyzed for M2eC-specific IgG subclasses by ELISA using 3M2eC protein (C) and
M2e-specific IgG Ab by ELISA using M2e-expressing Hela cells (D). N.D., not detected. The dashed line shows the limit of detection. The results are
expressed as the means+S.D. for the group (n=5). The data are representative of three independent experiments. Significant differences were
expressed as *, P,0.05, **, P,0.01, ***, P,0.005, respectively.
doi:10.1371/journal.pone.0027953.g002
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PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27953Figure 3. Cross-protection against infections with different influenza virus subtypes. Six-week-old female BALB/c mice (n=6) were
immunized twice with 10 ug of 3M2eC protein plus 2 ug of CT at 2 week intervals via i.n. or s.l., or with 10 ug of 3M2eC protein plus alum by i.d. or
i.m.. They were challenged i.n. with 10 LD50 of mouse adapted PR8 strain (H1N1) at 3 weeks (A and B), A/Aquatic Bird/Korea/W81/05 virus (H5N2) at 3
weeks (C and D) or A/Philippine/2/82 (H3N2) virus at 5 weeks (E and F) after the last immunization. Survival rate and the body weight loss were
monitored daily after the challenge. The results are expressed as the means+S.D. for the group.
doi:10.1371/journal.pone.0027953.g003
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immunization group lost 20% of initial body weight and recovered
on day 7 after challenge. In contrast, all mice in systemic
immunization (i.m. and i.d.) groups lost more than 20% of initial
weight and failed to recover. They all died within 8 days of the
infection (Fig. 3D). We further examined cross-protective immunity
against H3N2 virus, one of the seasonal strains that contain only 1
amino acid mismatched with M2e sequence of PR8 virus. As shown
in Fig. 3E, i.m. immunization route induced partial cross-
protection, whereas s.l. administration provided complete protec-
tion against challenge with lethal dose of mouse-adapted H3N2
virus. In addition, the s.l. immunization group showed rapid
recovery from the weight loss compared to that seen in i.m.
immunization group (Fig. 3F). Taken together, the results showed
that although s.l. immunization with 3M2eC vaccine candidate
inducedlowerlevelofAbsinplasma(Fig.2Cand D),itissuperiorto
systemic immunizations in induction of protection against infections
with virus containing identical or mismatched M2e sequence.
Protection against the 2009 pandemic influenza A virus
(H1N1)
Because of the emergence of 2009 pandemic influenza virus and
its establishment in human populations as a seasonal flu strain, we
tested whether s.l. immunization with 3M2eC protein induces
protection against challenge with 2009 pandemic H1N1 strain,
which has 5 mismatched amino acids in the M2e sequence of PR8
virus. Mice were immunized sublingually with 3M2eC and
challenged with A/CA/04/09 (H1N1) 5 weeks after the last
immunization. Five days after the challenge, viral titers in the
lungs were determined by EID50 assay. Significantly reduced viral
titers were observed in groups of mice immunized via i.n. or s.l.
route as compared to that in control group (Fig. 4A). Moreover,
morbidity as assessed by loss of body weight was less in the
immunized mice compared to the unimmunized control group
(Fig. 4B). This result demonstrates that s.l. immunization with
3M2eC protein induced protection against infection with 2009
pandemic influenza virus in mice.
S.l. or i.n. immunization with 3M2eC induced specific Ab
responses in respiratory tract
Since s.l. immunization with 3M2eC vaccine candidate induced
better protection even with lower level of specific Abs induced in
plasma as compared to systemic immunizations, we reasoned that
s.l. immunization induced mucosal immune responses that are
associated with protection. We determined levels of specific Abs in
saliva, nasal wash and bronchoalveolar lavage (BAL) two weeks
after the last immunization. We found that i.n. or s.l. immuniza-
tion with 3M2eC induced significantly higher level of 3M2eC-
specific IgA in saliva, nasal wash and BAL (P,0.05). In contrast,
systemic immunization routes failed to elicit specific IgA (Fig. 5A).
It has been recently shown that protection elicited by M2 vaccine
is mediated by IgG-dependent alveolar macrophages in BAL [37].
We further examined 3M2eC-specific IgG level in BAL. Indeed,
the levels of 3M2eC-specific IgG induced in mice immunized via
s.l. or i.n. were significantly higher than those induced in the mice
immunized via systemic routes (Fig. 5B). In addition, we
enumerated the M2eC-specific Ab secreting cells (ASCs) in the
lung tissues, the site of infection. We found significantly (P,0.05)
high numbers of 3M2eC-specific IgG and IgA ASCs in the lung
tissue of the mice immunized via i.n. or s.l. route (Fig. 5C), while
only a few ASCs were observed in the lung tissues of i.m. or i.d.
immunized mice. The results suggest that Ab responses induced in
the lungs upon mucosal immunization with M2-based vaccine are
important for protection against influenza virus infection.
Discussion
In this study, we demonstrate that s.l. administration of a
recombinant trimeric M2e protein construct adjuvanted with CT
Table 1. Variations of M2e sequences among influenza A viruses.











10,551 M2e sequences of influenza A virus strains were obtained from NCBI. These sequences were aligned with PR8-M2e sequence as a reference.
*denoted conserved sequence among the M2e sequences.
doi:10.1371/journal.pone.0027953.t001
Table 2. Comparison of M2e sequences used in the present
study.
Virus strain Subtype Amino acid sequence
A/PR/8 (H1N1) SLLTEVETPIRNEWGCRCNGSSD
A/Aquatic bird/Korea (H5N2) SLLTEVETPTRNGWECKCSDSSD
A/Philippine/2/82 (H3N2) SLLTEVETPIRNEWGCRCNDSSD
A/CA/04/09 (new H1N1) SLLTEVETPTRSEWECRCSDSSD
M2e sequences were aligned with PR8-M2e sequence as a reference. The
different amino acids from M2e sequence of PR8 virus are in bold.
doi:10.1371/journal.pone.0027953.t002
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PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27953Figure 4. Protection against the 2009 pandemic influenza A virus (H1N1). Mice were immunized i.n. or s.l. with 3M2eC (10 ug) plus CT
(2 ug) on days 0 and 14 and challenged by i.n. administration of A/CA/04/09 (H1N1) 5 weeks after the last immunization. (A) Virus titers in the lung
tissue at day 5 after challenge were determined in embryonated chicken eggs. (B) Body weight was monitored daily after the viral challenge. The
results are expressed as the means+S.D. for the group. Significant differences were expressed as *, P,0.05.
doi:10.1371/journal.pone.0027953.g004
Figure 5. 3M2eC-specific Ab levels in secretions and lung tissues. Mice were immunized with 10 ug of 3M2eC protein plus 2 ug of CT via i.n.
or s.l., or with 10 ug of 3M2eC protein plus alum via i.d. or i.m. on day 0, 14, and 28. Saliva, nasal wash and BAL were collected two weeks after last
immunization. M2e-specific IgA in the secretions (A) and M2e-specific IgG in BAL (B) were determined by ELISA using 3M2eC protein. (C) Number of
M2e-specific IgG or IgA Ab secreting cells in the lung tissue at day 7 after last immunization was determined by ELISPOT using 3M2eC protein. N.D.,
not detected. The dashed line shows the limit of detection. The results are expressed as the means+S.D. for the group (n=5). The data are
representative of three independent experiments.
doi:10.1371/journal.pone.0027953.g005
Sublingual Immunization of M2-Based Vaccine
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27953induces protection against a lethal challenge with wild-type
influenza virus. Protection conferred by s.l. M2e vaccine construct
was superior to that induced by systemic immunizations. Although
the level of M2e-specific serum IgG Ab after s.l. immunization was
lower than those seen after systemic immunizations, s.l. immuni-
zation induced higher M2-specific Ab titers in saliva, nasal wash
and BAL, as well as M2-specific ASCs in lung tissues. Our results
clearly suggest that specific Abs induced in mucosa-associated
tissues after s.l. immunization are important for protection in M2-
based vaccine against infection with influenza A viruses.
M2e, being relatively highly conserved among the influenza A
viruses, has been considered a most promising influenza vaccine
antigen [9]. A number of strategies have been developed to induce
cross-protection using M2e-based vaccines [18,24,25]. The most
common of these strategies involves systemic such as s.c. or i.m.
administration of the antigen but protection has often been rather
limited [14,15]. In keeping with these observations, our study
indicates that systemic administration with two doses of 3M2eC
conferred partial and in some cases no protection against
challenge with different virus subtypes. In most studies, systemic
immunization with at least three doses of M2-based vaccine was
required to achieve full protection [19,21,38,39]. Other studies
have shown that systemic administration of two doses of M2-based
vaccine induced protection against challenge with relatively low (1
LD90 or 4 LD50) doses of wild type influenza virus [24,40].
In our study, two doses of 3M2eC via systemic routes conferred
partial or no protection against the challenge with 10 LD50 of
influenza A viruses. However, i.n. immunization with two doses of
3M2eC conferred full protection against challenge with different
influenza A virus subtypes. These findings support the observa-
tions that the i.n. route, a mucosal route, is superior to systemic
administration routes for promoting cross-protective immunity in
mice [18,26,34]. Importantly, our study demonstrates for the first
time that s.l. immunization with just 2 doses of M2-based vaccine
candidate induced broad protection against challenge with
relatively high dose of lethal influenza A virus.
The mechanisms by which Abs against M2e mediate cross-
protection are not fully understood. In this study, we show that
M2e-specific Ab responses are induced in the lungs after mucosal
(s.l. or i.n.) rather than systemic (i.m. or i.d.) administration, and
these responses are associated with protection against influenza
virus infection. These results further support recent findings that
anti-M2e IgG Abs are involved in protection through interaction
with Fc receptors expressed on alveolar macrophages [37]. Indeed,
we found significant levels of anti-M2e IgG induced in BAL and
ASCs in the lungs after s.l. or i.n. but not systemic immunization.
Several studies have reported that Abs to N-terminus of M2e
inhibit replication of influenza A virus [11] and that adoptive
transfer of monoclonal Abs to an epitope located between position
1 and 10 on the N-terminus sequence of M2e protect against
influenza A virus challenge [41,42]. In our study, protection
against highly heterologous influenza viruses upon s.l. immuniza-
tion with M2-based vaccine is probably due to induction of Abs to
N-terminus (position 1–10) of M2e sequence that is identical to the
sequences of the viruses used for challenge in our study.
We showed that the i.n. route conferred complete protection
against homologous and heterologous challenges, suggesting that
i.n. administration is potent to induce protection against multiple
subtypes of influenza A virus. However, it has remained a safety
issue for human use due to accumulation of antigens to CNS
[30,31]. In contrast with i.n., the s.l. route is considered to be safe,
since redirection of an antigen to the CNS does not occur [32,33].
Our previous study has demonstrated that s.l. immunization with
ovalbumin induced significant mucosal and systemic immune
responses, as well as cytotoxic T cell response in lung tissue [32].
In addition, s.l. administration with inactivated influenza virus
provided protection against influenza virus challenge without
redirecting the immunogen to the CNS [33]. However, it is not yet
clear how s.l. immunization could induce Ag-specific Ab responses
in the lung mucosa.
Recently, there has been some concern regarding the possible
emergence of a new influenza pandemic by reassortment between
animal and human viruses [43]. In fact, new pandemic H1N1
virus occurred worldwide in 2009 resulting in significant morbidity
and mortality [44]. After the first human infection in Hongkong
[45], highly pathogenic avian influenza virus H5N1 (HPAIV)
caused number of human infections with a death rate of more than
50% and remains a global threat [46]. For pandemic influenza
preparedness development of universal influenza vaccines against
various subtypes is urgent. Our vaccination strategy of combina-
tion of s.l. immunization, a safe mucosal route, with M2-based
vaccine provided broad protection against different influenza. Our
vaccination strategy offers a new tool for control of influenza
outbreaks including future pandemics. Of note, the protection
against the wide range of the viruses containing mismatched
amino acids ranging from 0 to 6 out of 23 amino acids of M2e
from PR8 strain was observed.
During a pandemic, the availability and rapid mobilization of
medical care personal is critical for effective mass vaccination [47].
Since s.l. mass immunization could be implemented without
requiring trained healthcare personnel, this approach may be
deployed under complex emergency situations such as during the
early stage of an epidemic outbreak.
In conclusion, our results demonstrate that s.l. immunization
with an M2e-based vaccine formulation is efficacious against
experimental infection in mice. These findings may offer an
approach to control epidemic and pandemic influenza infections.
Materials and Methods
Construction of plasmids expressing M2eC or 3M2eC
protein
A gene (Fig. 1A) encoding three tandem copies of M2e
conjugated to C-terminus sequence of M2 protein without residues
26–55 from influenza A/Puerto Rico/8/34 (H1N1) virus was
chemically synthesized by Bio S&T Inc. (Canada). The gene has
an Nde I site between 2
nd and 3
rd M2e region. For the plasmid
expressing 3M2eC, the gene was digested with Xho I and BamH I
and inserted into the bacterial expression vector pET15b
(Novagen, Madison, WI) to express as a fusion of his-tag at the
N terminus, resulting in the plasmid pET15b-3M2eC. For the
construct expressing M2eC protein, which has one M2e domain,
the synthesized gene was digested with Nde I and BamH I, and
then inserted into pET15b vector.
Expression and purification of M2eC or 3M2eC proteins
E. coli BL21 (DE3) strains (Novagen) transformed with these
plasmids were grown overnight at 37uC in Luria-Bertani (LB)
medium supplemented with 100 ug/ml of ampicillin. The
overnight culture was transferred into fresh LB medium and
cultured at 37uC while shaking at 180 rpm until OD600 of
0.6,0.8. Each protein expression was induced by adding IPTG
(isopropyl b-D thiogalactoside) to a final concentration of 0.5 M
for 4 hrs and the cells were harvested by centrifugation at
6,000 rpm for 10 min. The cell pellets were suspended in binding
buffer (20 mM Tris, 0.5 M NaCl, pH 7.9) and disrupted by
sonication on ice. Then, the soluble and insoluble fractions were
separated by centrifugation for 40 min at 20,000 rpm. The soluble
Sublingual Immunization of M2-Based Vaccine
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Palo Alto, CA). The columns were washed with binding buffer
containing 20 mM imidazole, and then the proteins were eluted
by an elution buffer (300 mM imidazole, 20 mM Tris, 0.5 M
NaCl, pH 7.4), followed by desalting with PD3 column (Amer-
sham, IL, USA). The purified proteins were treated with 1%
Triton X-114 to remove endotoxin and incubated with rocking for
30 min at 4uC, followed by incubation in a 37uC water bath for
20 min. The phases containing endotoxin were separated by
centrifugation at 13,000 rpm for 5 min. This cycle was repeated
five times. Each protein was incubated with SM-2 beads (Bio-Rad,
Hercules, CA) for 2 hrs at 4uC to remove residual Triton X-114
and filtered through spin-X column (Costar, Lowell, MA). The
endotoxin level of each protein was measured by the limulus
amebocyte lysate (LAL) assay kit according to the instructions
(Lonza, Switzerland). Endotoxin levels of the proteins were less
than 5 EU/mg. The purified proteins were electrophoresed on
15% SDS-PAGE and the protein bands were visualized by
staining with Coomassie Brilliant Blue. The protein concentration
was determined by Bradford protein assay kit (Bio-Rad). The
purified proteins were stored at 280uC.
Western blot
The purified proteins were separated on 15% SDS-PAGE and
the gel was transferred onto a nitrocellulose membrane (Schleicher
& Schuell, Germany) by using a semi-dry transblot apparatus (Bio-
Rad). The membrane was blocked with Tris-buffered saline (TBS)
containing 5% skim milk for 30 min at room temperature and
incubated with M2e specific Ab (14C2) [8] at 1:1,000 dilution in
TBST (TBS and 0.05% Tween 20) containing 5% skim milk for
1 hr at room temperature. After washing with TBST, the
membrane was probed with Goat-anti mouse IgG conjugated
with horseradish peroxidase (Santa Cruz biotechnology, Dela-
ware, CA) at 1:3,000 dilution in TBST containing 5% skim milk
for 1 hr at room temperature and detected with an ECL kit
(Amersham).
Mice and immunization
Specific pathogen free, female BALB/c mice aged 6 weeks
were purchased from Orient Bio Inc. (Korea). All mice were
maintained under specific pathogen-free conditions and all
studies were approved by Institutional Animal Care and Use
Committees (IACUC) at Yonsei University (2010-00-32619),
Chungbuk University (BLS2011-0003) and International Vaccine
Institute (2010-017). In order to compare immune response
between 3M2eC and M2eC proteins, five mice per group were
anesthetized with ketamine and immunized i.n. with 20 ul
containing 10 ug of M2eC, 3M2eC alone, or with 2 ug of CT
(LIST BIOLOGICAL LABS INC. Campbell, CA) on day 0 and
14. To compare protective immunity depending on the route,
mice were immunized with 10 ug of 3M2eC protein plus 2 ug of
CT by i.n. or s.l., or with 10 ug of 3M2eC plus alum by i.d. or
i.m. on day 0 and 14. For i.n. immunization, total 20 ul of
prepared vaccines were administered into each nostril of the
anesthetized mice. For s.l. immunization, the anesthetized mice
were immunized with 15 ul of vaccines underneath the tongue
using a pipette. Following s.l. immunization, mice were
maintained with heads placed in ante flexion for 30 min. For
i.d. immunization, the anesthetized mice’s chests were shaved.
The needle was inserted into the skin nearly parallel to the plane
of the skin and 100 ul of vaccines were administered per mouse.
For i.m. immunization, 100 ul of vaccines were injected into the
thigh muscles of mice.
Sample collection
Sera and mucosal samples were collected on days 13 or 14 after
the last immunization. Blood was collected from the retro-orbital
plexus, incubated at room temperature for 30 min and the sera
were obtained from the blood by centrifugation for 10 min at
13,000 rpm. Saliva samples were obtained after inducing salivary
gland secretion by i.p. injection of pilocarpine (100 ug per animal)
(Sigma, St. Louis, MO). For BAL samples, the mice were dissected
to expose the trachea and then IV catheter (BD Biosciences, San
Jose, CA) was inserted into a small nick of the trachea. BAL
samples were collected by repeated flushing and aspiring with
500 ul of PBS into the lungs. Nasal washes were collected by
flushing with 50 ul of PBS two times through the nasal cavity. The
samples were stored at 280uC until used.
ELISA
Ab titers were measured by enzyme-linked immunosorbent
assay (ELISA) using serum or mucosal samples from each mouse
(n=6). The 96-well ELISA plates (Nunc, Roskilde, Denmark)
were pre-coated with 100 ul of 3M2eC protein (2 ug/ml) in
50 mM Sodium bicarbonate buffer (pH 9.6) overnight at 4uC.
After blocking with PBS containing 5% skim milk for 1 hr at room
temperature, 100 ul of serial 2- or 3-fold diluted samples in
blocking buffer were added to each well and incubated for 1 hr at
37uC, followed by addition of 1:3,000 diluted horseradish
peroxidase-conjugated goat anti-mouse IgG, IgG1, IgG2a, or
IgA (Santa Cruz biotechnology). After incubation for 1 hr at room
temperature, 100 ul of peroxidase substrate tetramethylbenzidine
(TMB) (Millipore, Bedford, MA) was added to each well. The
reaction was stopped by adding 0.5 N HCl. The absorbance at
wavelength 450 nm was recorded by an ELISA reader (Molecular
Devices, Sunnyvale, CA). The endpoint titer was determined by
O.D. cut-off values of 0.2.
M2 expressing Hela cell-based ELISA
M2 expressing Hela cells in RPMI1640 containing doxycycline
(0.5 ug/ml) were dispensed at 1610
5 cells per well into 96-well
plates. Next day, the plates were fixed by addition of 80 ul of 80%
acetone, followed by washing with PBS for three times. Serum IgG
titers to M2 expressing Hela cells (M2e) were determined by
ELISA as above.
ELISPOT assay
Mice (n=5) were immunized on day 0, 14, and 28 as described
above. On day 7 after the last immunization, the mice were
anesthetized and the lungs were removed into RPMI medium. To
obtain the lung cell suspension, the tissues were minced with
scissors and incubated for 1 hr at 37uC in RPMI medium
containing 0.5 mg/ml collagenase D (Roche Applied Science,
Indianapolis, IN) and 100 mg/ml of DNase (Sigma-Aldrich).
Following incubation, the cell suspensions were obtained by
passing gently through a 100 um Falcon cell strainer (BD
Labware). The number of M2-specific ASCs in the lung cell
suspensions was calculated by using ELISPOT assay. 96-well
nitrocellulose microplates (Millipore) were coated with 3M2eC
(10 ug/ml) in PBS overnight at 4uC. Next day, the plates were
blocked with RPMI-1640 (Cambrex, Walkersville, MD) contain-
ing 10% FBS (complete medium) for 30 min at 37uCi n5 %C O 2
incubator. The lung cell suspensions were transferred to ELI-
SPOT plates at 2-fold dilutions, followed by addition of HRP
conjugated goat anti-mouse IgG or IgA (1:500) (Southern
Biotechnology Associates, Birmingham, AL). After incubation for
4 hrs in a 37uC, 5% CO2 incubator, the plates were extensively
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27953washed with PBS, PBS-T, water, sequentially. Spots were
developed by addition of AEC-H2O2 chromogenic substrate
(Sigma-Aldrich) and counted by using an ELISPOT reader
(Molecular devices)
Virus challenge
For the homologous challenge, the immunized mice were
anesthetized and then challenged i.n. with 10 LD50 (40 TCID50)o f
mouse adapted influenza A/Puerto Rico/8/34 (H1N1) virus three
weeks after the final vaccination. For the heterologous challenge,
the immunized mice were infected with 10 LD50 (89 TCID50) of
mouse adapted A/Aquatic Bird/Korea/W81/05 (H5N2) virus
three weeks after the final vaccination or with 10 LD50 (320 PFU)
of mouse adapted A/Philippine/2/82 (H3N2) virus five weeks
after the last vaccination. The mice were monitored daily for
weight loss and survival rate following the viral challenge. Survival
rate was determined by death or a cut-off of 25% in body weight
loss at which point animals were euthanized.
Virus Titers in lung tissues
Mice (n=5) were immunized i.n. with 20 ul containing 10 ug of
M2eC, 3M2eC alone, or with 2 ug of CT as adjuvant,
administered 2 weeks apart. Five weeks after last vaccination,
mice were i.n. challenged with 30 ul (3610
3 TCID50) of the A/
CA/04/09 (H1N1) virus. Mice were continuously observed for 12
days post infection (dpi). Lung tissue samples of mice were
collected at 5 dpi and homogenized in PBS containing antibiotics.
Tissue homogenates were centrifuged at 12,0006 g and
supernatants were transferred to new tubes. All samples were
immediately serially diluted 10-fold and then inoculated into 11-
day-old embryonated chicken eggs for virus titration as computed
by the Reed and Muench method with results expressed as
(EID50/ml) [48].
Statistical analysis
Statistical tests were performed by using Student’s t test. A P
value of less than 0.05 was considered significant.
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